Biocon to fully integrate Biocon Biologics; to acquire Viatris’ remaining stake via share swap

The board has also approved the swap ratios for the transaction and cleared a proposal to raise up to ₹4,500 crore (about $500 million) through a qualified institutional placement, subject to shareholder approval.

Leave a Reply

Your email address will not be published. Required fields are marked *